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Inflammatory breast cancer (IBC) is a rare but very aggressive form of locally advanced 
breast cancer (1-6% of total breast cancer patients in United States), with a 5-year overall 
survival rate of only 40.5%, compared with 85% of the non-IBC patients. So far, a unique 
molecular signature for IBC able to explain the dramatic differences in the tumor biology 
between IBC and non-IBC has not been identified. As immune cells in the tumor 
microenvironment plays an important role in regulating tumor progression, we hypothesized 
that tumor-associated dendritic cells (TADC) may be responsible for regulating the 
development of the aggressive characteristics of IBC. MiRNAs can be released into the 
extracellular space and mediate the intercellular communication by regulating target gene 
expression beyond their cells of origin. We hypothesized that miRNAs released by IBC cells 
can induce an increased activation status, secretion of pro-inflammatory cytokines and 
migration ability of TADC. In an in vitro model of IBC tumor microenvironment, we found 
that the co-cultured of the IBC cell line SUM-149 with immature dendritic cells (iDCSUM-149) 
induced a higher degree of activation and maturation of iDCSUM-149 upon stimulation with 
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lipopolysaccharide (LPS) compared with iDCs co-cultured with the non-IBC cell line SUM-
159 (iDCSUM-159), resulting in: increased expression of the costimulatory and activation 
markers; higher production of pro-inflammatory cytokines (TNF-, IL-6); and 3) higher 
migratory ability. These differences were due to the exosome-mediated transfer of miR-19a 
and miR-146a from SUM-149 and SUM-159, respectively, to iDCs, causing the 
downregulation of the miR-19a target genes PTEN, SOCS-1 and the miR-146a target genes 
IRAK1, TRAF6. PTEN, SOCS-1 and IRAK1, TRAF6 are important negative and positive 
regulator of cytokine- and TLR-mediated activation/maturation signaling pathway in DCs. 
Increased levels of IL-6 induced the upregulation of miR-19a synthesis in SUM-149 cells 
that was associated with the induction of CD44+CD24-ALDH1+ cancer stem cells (CSCs) 
with epithelial-to-mesenchymal transition (EMT) characteristics. 
In conclusion, in IBC tumor microenvironment IL-6/miR-19a axis can represent a self-
sustaining loop able to maintain a pro-inflammatory status of DCs, leading to the 
development of tumor cells with high metastatic potential (EMT CSCs) responsible of the 
poor prognosis in IBC patients.  
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BACKGROUND ON BREAST CANCER 
Over the past decades, the rates of death for breast cancer have seen a steady 
decrease, mainly in younger women. This is mostly due to the improvement in screening 
methods, the development of more effective and less toxic treatment and the progress in 
the earlier detection. Nevertheless, breast cancer still remains the second leading cause 
of death in women after lung cancer, with 232,340 estimated new cases (accounting for 
29% of all new cancer cases among women) and 39,620 estimated deaths in 2013 in US 
(1, 2).  
Breast cancer is a heterogeneous disease characterized by a wide spectrum of 
clinical and molecular factors that identify distinct biological subtypes. Based on the 
immunohistochemical (IHC) markers (the estrogen receptors: ER+; progesterone 
receptor: PR+; the amplification of the human epidermal growth factor receptor 2: 
HER2+) and gene expression studies using the cDNA microarray, five major breast 
cancer subtypes have been identified: luminal A (ER+ and/or PR+, HER2-, Ki-67<14%); 
luminal B (ER+ and/or PR+, HER2-, Ki-67≥14% or ER+ and/or PR+, HER2+); HER2+ 
(ER-, PR-, HER2+); basal-like (ER-, PR-, HER2- “triple-negative” breast cancer (TNBC) 
with cytokeratin (CK) 5/6 and/or 17 positive and/or epidermal growth factor receptor 
(EGFR) positive and normal breast-like tumors (3-5). As the majority of the TNBC 
(approximately 80%) breast cancer express basal-like genes, triple-negative and basal-
like breast cancer are considered synonymous (6). The distinct subtypes are 
characterized by different biological, clinical and pathological features that account for 
different responsiveness to treatment and outcome. Particularly, the hormone receptors 
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positive breast cancers (ER+ and/or PR+, HER2-) are the most common type of breast 
cancer, representing approximately 70% of invasive breast cancers (7) and have been 
associated with the most favorable prognosis. The HER2+ breast cancers represent 
approximately 15-20% of invasive breast cancers and the overexpression of HER2 is 
associated with an increased aggressiveness and shorter survival (8). The TNBC 
represents the 12-17% of invasive breast cancers and is one of the most aggressive and 
lethal subtypes (3, 4, 9-11) characterized by high proliferative rate, genetic instability, 
high histological grade, and poor differentiation.  
TRIPLE NEGATIVE BREAST CANCER 
Compared with the other subtype, TNBC is a very heterogeneous disease and 
presents a higher degree of complexity, as it exhibits a wide spectrum of clonal 
genotypes (12) and encompasses additional molecular subtypes: the claudin-low 
subgroup, which are enriched in cells with stem cell (CD44+CD24- and ALDH1+) and 
epithelial-to-mesenchymal transition features; the interferon-rich subgroup characterized 
by better prognosis compared with other TNBC; and the normal-breast-like subgroup 
which may represent an artifact due to contamination of  cell from normal epithelium 
(stromal and normal cells) (13). More than 75% of breast cancers positive for BRCA1 
mutation have TN phenotype, while up to 70% of TNBC had overexpression of EGFR 
and more than 50% had alteration of PTEN expression (loss of heterozygosis, 
chromosomal instability, epigenetic silencing)(13-16). As TNBC do not express ER, PR 
and HER2 receptors, they cannot benefit form target therapy, like the tamoxifen and 
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trastuzumab for ER+/PR+ and HER2+ breast cancer patients. TNBC are treated 
exclusively with conventional chemotherapy and there is no preferred standard for of 
chemotherapy. Although a minority of patients may achieve complete pathological 
response and excellent outcome, the majority of patients fail to achieve complete 
pathological response and their prognosis is poorer than patients of the other subtypes 
(17). As little is know on the pathogenesis of TNBC/basal-like, the elucidation of the 
molecular and biological mechanisms that drive this subtype of breast cancer will have 
an important impact in the development of new druggable targets. 
BACKGROUND ON INFLAMMATORY BREAST CANCER 
The inflammatory breast cancer (IBC) is a rare disease (~ 5% of all diagnosed breast 
cancer), but it is the most aggressive form of locally advanced breast cancer 
(LABC)(18). Contrary to the steady decreasing incidence of non-IBC breast cancer, IBC 
incidence continues to increase (19). IBC is characterized by fast progression, high 
invasiveness, highly angiogenic ability and lymphovascular invasion (LVI) (20) that 
accordingly confer to IBC an extremely high metastatic potential. Indeed, at diagnosis 
the majority of the patients present with advanced disease, with the involvement of 
axillary lymph nodes and distant metastases for ~35% of patients. IBC often shows high 
histological grade and negativity for hormone receptors (HR) and triple negative IBC are 
associated with poor prognosis (21). Despite the advances in the multidisciplinary 
treatments, IBC remains the most lethal type of LABC and the prognosis remain much 
less favorable with a 5-year overall survival rate of only 40.5%, compared with 85% of 
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the non-IBC patients (22). The diagnosis is mainly based on clinical and pathological 
criteria. Symptoms have characteristic features at presentation and include diffuse skin 
erythema (at least one-third of the breast) and oedema (more than two-thirds of the 
breast), peau d’orange, swelling, tenderness, induration and warmth in the breast. The 
pathological hallmark of IBC is represented by dermal lymphatic involvement with the 
presence of tumor emboli in the dermal lymphatic vessels, as a result of the high 
migratory and invasive capability. This is required by pathologist to confirm the clinical 
diagnosis (T4d according to the TNM staging criteria). However, in some instances, the 
clinical and pathologic findings may not concord for the diagnosis of IBC. Indeed, the 
dermal lymphatic invasion is identified in only 50-75% of IBC cases (23) and the 
changes of the skin may derive from acute mastitis or non-IBC advanced breast cancer. 
Therefore, the distinction from non-IBC may result difficult and this may lead to a 
misdiagnosis of IBC.  
So far, there are no molecular diagnostic and prognostic biomarkers available for 
IBC and little is know about the molecular mechanism and genetic alterations that could 
explain the higher aggressiveness and poor prognosis of IBC compared with non-IBC. 
Their identification would help to improve the accuracy of diagnosis and develop new 
target therapy. Despite the effort to establish a molecular signature able to distinguish 
IBC from non-IBC, the results generated by several studies are poorly comparable and 
overlapping. Recently, a comprehensive analysis of three large datasets generated by the 
World IBC Consortium showed that a very small number of genes have a uniquely IBC-
specific gene expression (24). This small difference in the gene expression profile might 
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not explain the difference in the behavior of tumor cells. Therefore, it is conceivable that 
the complex network of interactions among cells in the microenvironment may play a 
relevant role in determining the relevant differences in the degree of aggressiveness and 
clinical outcome of IBC compared non-IBC. In the tumor microenvironment, the cross-
talk between cancer cells and tumor associated cells is particularly relevant in promoting 
tumor progression and metastasis formation. 
Metastasis is the final step of cancer progression and represents the major cause of 
death by cancer. About 90% of the deaths of cancer patients are determined by 
development of metastases rather than primary disease (25). Important step in the 
process of metastasis formation is the acquisition of invasive and migratory ability by 
tumor cells that allows tumor cells to invade the surrounding tissue, gain access to the 
neovasculature and disseminate to distant organ. These two biological characteristics are 
particularly important in IBC, as they are responsible of the fast progression (26, 27). It 
is a traditional notion that tumor cells disseminate at later stage during the cancer 
development. However, recently, gene expression profiling studies have challenged this 
concept (28). Indeed, tumor cells capable to disseminate and give rise to metastases are 
already present at early stage of the disease, are genetically predetermined, and different 
from the other cells in the primary tumor (29, 30). Indeed, in a epidemiological analysis 
involving more than 12,000 breast cancer patients, it was reported that metastasis might 
have started already 5-7 years before the primary tumor diagnosis (31). In addition, the 
presence of disseminated tumor cells (DTCs) in the bone marrow of early stage cancer 
  7
patients without evident metastases supports the concept of early dissemination of tumor 
cells (32).  
TUMOR MICROENVIRONMENT 
Besides the genetic changes, also the paracrine cross-talk between cancer and 
bystander cells in the tumor microenvironment has been shown to play an important role 
at early stage in the regulation of tumor dissemination and promotion of metastasis 
formation (33-38). In fact, tumor is a heterogeneous population of cells consisting not 
only of cancer cells, but also endothelial cells, mesenchymal cells, fibroblasts and 
immune cells (33). All of these cell types are involved in the regulation tumor 
microenvironment homeostasis that is harnessed by tumor cancer cells to favor their own 
survival. Over the past years, more insights have been gained on the complex 
relationship between immune and tumor cells and on the role of immune system in the 
regulation of tumor development and progression (36, 39-41). In the tumor 
microenvironment immune cells paradoxically play two opposite roles in the regulation 
of tumor cell dissemination during the early stage of tumor progression. Indeed, they can 
have an anti-tumor activity by killing the developing cancer cells that start accumulating 
mutations and therefore they can prevent tumor cell dissemination (cancer 
immunosurveillance)(42-44). On the other hand, immune cells can contribute to tumor 
formation and progression by their chronic activation status and secretion of pro-
inflammatory cytokines, like TNF-, IL-1, IL-6, IL-8, TGF-, VEGF, IFN- (chronic 
inflammation) (33, 36, 39, 45, 46). DCs play a central role in the regulation of tumor 
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microenvironment immune responses by orchestrating both the innate and adaptive arms 
of the immune systems. DCs reside in the tissue as immature dendritic cells (iDCs), 
characterized by low levels expression of the costimulatory (CD80, CD86, CD40) and 
activation/maturation (CD83, HLA-DR) surface markers and low secretion of cytokines. 
In this status, iDCs maintain the immunological homeostasis in the tissue. At early stage, 
when tumor cells start to develop and proliferate, two major scenarios can occur. First, 
tumor cells can induce activation of tumor-associated iDCs that subsequently upregulate 
the expression of CD80, CD86, CD40, CD83, HLA-DR and cytokine secretion leading 
to effective immune responses. Indeed, according to the pattern of cytokines that 
activated DCs secrete three different T cell-mediated responses can be induced: 1) IL-1, 
IL-6, TGF-, IL-21 and IL-23 induce the differentiation of Th-17 cell that mediate pro-
inflammatory responses (IL-17, IL-21, IL-22); 2) IL-12 and IL-18 induce the 
differentiation of Th1 cells that activate cell-mediated anti-tumor responses that are able 
to eradicate cancer cells (antigen-specific CD8+ T cytotoxic lymphocytes: CD8+ CTL; 
and natural killer cells: NK) by the secretion of IFN- and IL-2; and 3) IL-4 and IL-10 
induce the differentiation of Th2 cells that inhibit the anti-tumor responses Th1-mediated 
by the secretion of IL-4, IL-5 and IL-13 (47, 48). In the second scenario, tumor cells 
may not induce activation of tumor-associated iDCs that remain in an immature status 
and therefore are not able to induce effective immune responses (Th-17, Th1 or Th2). 
On the contrary iDCs induce the differentiation of the immunosuppressive T regulatory 
(Treg) cells by TGF- secretion leading to a general suppression of the immune cell 
function and therefore determining the tumor immune escape. 
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DCs can also drive a tumor promoting response directly by sustaining chronic 
inflammation by secretion of high levels of TNF-, IL-1, IL-6 and recruiting 
polymorphonuclear leucocytes (PMNLs) by IL-8 (39, 40, 49). Furthermore, DCs can 
also contribute to tumor progression by promoting tumor angiogenesis (36, 50), 
supporting the development and expansion of breast cancer stem cells (BCSC) (33, 46, 
51-54) and by activating T cells and macrophages (55) to secrete the EMT-inducing 
cytokines TGF-, IL-6, TNF- (56). EMT is a biological process in which epithelial 
cells lose their epithelial characteristics and acquire a mesenchymal phenotype along 
with increased migratory and invasive behavior. Particularly, epithelial cells lose the 
epithelial morphology, the intercellular adhesion molecule (E-cadherin), the epithelial 
marker (cytokeratin) and acquire the mesenchymal markers (fibronectin, N-cadherin, 
and vimentin), spindle-like morphology and increased motility, invasiveness and 
metastatic ability. It is know that the EMT process in involved not only in the induction 
of increased tumor migration and invasion during the metastatic process, but also in the 
generation of cancer cells with stem cell-like characteristics that acquire resistance to 
chemo- and radiotherapy (57). 
On the other hand, tumor cells can negatively regulate the effector function of 
immune cells in the tumor microenvironment by developing multiple strategies able to 
elude the anti-tumor immune responses (42). These strategies include mechanisms able 
either to prevent and hinder the activation of an effective anti-tumor immune response 
(tumor escape) by the secretion of immunosuppressive cytokines (TGF- and IL-10) or 
impair tumor recognition by immune effector cells through the downregulation of tumor 
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cell surface markers (tumor specific antigen, MHC class I molecules, immune-cell 
activatory/costimulatory ligands) and death-receptor signaling pathways (Fas, TNF 
receptors). Genetic and epigenetic alterations that occur at early stage of tumor 
development may drive the acquisition of resistance to immune cell-mediated detection 
and elimination of tumor cells resulting in tumor growth (immunoediting). Therefore, at 
early stage, tumor cells with high aggressive characteristics, like increased migratory, 
invasive ability and EMT/CSC-like phenotype may be induced by a pro-inflammatory 
tumor microenvironment, can be positively selected by immunoediting, can disseminate 
to distant organ by the acquisition of migratory, invasive ability and finally generate 
micrometastasis even before primary tumor can become clinically detectable. 
We can conclude that at early stage, immune cells play an important role in the 
determining the fate of tumor cells in terms of tumor-promoting or anti-tumor immune 
responses.   
CIRCULATING MIRNAS  
In the tumor microenvironment there is a continuous crosstalk between tumor and 
tumor associated immune cells. This communication is mediated mainly by cytokines, 
growth factor and cell-to-cell interactions. However, recently it was reported that a new 
intercellular messenger can regulate the crosstalk: circulating microRNAs (miRNAs). 
MiRNAs are small noncoding RNA molecules typically of 18-24 nucleotides in size 
with regulatory functions. They modulate the translation of specific target mRNAs by 
binding either to the complementary sequences in the 3’ untranslated regions (3’ UTR) 
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of mRNA or to the amino acid coding sequence (CDS) of the mRNA (58). This binding 
determines the inhibition of gene expression through either the degradation or the 
inhibition of translation by ribosomes or the localization to P-bodies of the target mRNA 
(59). It is estimated that in human cancers more than 50% of miRNAs are located in 
chromosomal regions subjected to genetic alterations (deletions, amplification, 
translocation and mutation) (60) and this determines an aberrant expression pattern in 
the tumor cells (61).  
Recently, it was reported that miRNAs can be detected outside the cellular 
environment and in biological fluids (serum, plasma, urine, milk, pleural fluid and 
saliva), as circulating miRNAs (62, 63). They can be secreted by cells into the 
extracellular space as a highly stable form of cell-free nucleic acids in three different 
fashion: 1) encapsulated in exosomes; 2) associated with Argonaute2 (Ago2) protein 
forming extracellular Ago2-miRNA complexes; or 3) contained inside apoptotic bodies 
(64-69). Therefore, miRNAs released through these ways can resist degradation by 
RNase in the extracellular space and when taken up they can regulate target gene 
expression beyond their cell of origin (64, 70-72). Immune cells can use circulating 
miRNAs to communicate and mediated their functions. Indeed, T and B lymphocytes 
can exchange functional miRNAs bidirectionally (73); DCs can take up EBV-encoded 
miRNAs secreted by EBV-infected B cells that are able to downregulate the expression 
of the immunostimulatory gene CXCL11 in DCs (74); DCs communicate with 
neighboring DCs through the transfer of functional microRNAs (75); and finally, 
miRNAs can be transferred from the IL-4 alternatively activated (M2) tumor-associated 
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macrophages (TAMs) into breast cancer cells and promote invasion ability in recipient 
breast cancer cells (76). 
Besides tumor cells, altered levels of miRNAs can be found also in the serum of 
cancer patients and their aberrant pattern may correlate with the dysregulated pattern of 
parental tumor (62, 63). However, as most of the circulating miRNAs originate from 
blood cells (77) it is conceivable to assume that serum miRNA pattern may reflect the 
overall pathological changes associated with the development of the disease with the 
contribution of both cancer and blood cells. Therefore, circulating miRNAs have a 
relevant potential use as clinical diagnostic and prognostic biomarkers (62, 63). 
MIR-19A AND MIR-146A EXPRESSION IN BREAST CANCER AND DCS 
MiR-146a and miR-19a are overexpressed in breast cancer and regulate the tumor 
progression. The expression of miR-146a is upregulated in the highly invasive MDA-
231 and SUM-159 breast cancer cell lines, compared with the less-invasive MCF-7 cells 
(78). Furthermore, miR-146a was found to be highly expressed in triple negative and 
basal-like breast cancer cells and be responsible of BRCA1 downregulation (miR-146a 
target), explaining the low levels of BRCA1 in about 30% of sporadic breast cancer (79). 
MiR-146a is also upregulated in breast cancer cells that developed cisplatin-resistance 
(80).  
MiR-19a belongs to the miR-17-92 cluster, composed by seven miRNAs: miR-17-
5p, miR-17-3p, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92-1 and was found to 
be overexpressed in breast (81, 82) and is the major player in the induction of 
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tumorigenesis (83). MiR-19a regulates tumor angiogenesis (84), induces c-Myc-
mediated lymphomagenesis and decrease apoptosis by the suppression of PTEN (85, 86) 
and it is overexpressed in a mouse model of human breast cancer bone metastasis (82).  
Besides tumor cells, miR-146a and miR-19a have regulatory functions also in DCs. 
Indeed, they can regulate the activation of iDCs by modulating the signaling pathways of 
TLR4 and CD40 upon binding with their ligands: lipopolysaccharide (LPS) and CD40L 
respectively. LPS in the major component of the gram-negative bacterial wall and is a 
strong activator of iDC to mount immune responses against bacterial infection. The 
binding of TLR4 with LPS induces the nuclear translocation of NF-kB and the 
subsequent activation of transcription of pro-inflammatory cytokines, like IL-1, IL-6, 
and TNF-(87). Also fatty acids can bind TLR4 inducing pro-inflammatory responses 
in the adipose tissue of obese mice and humans. This pathway is responsible of chronic 
inflammation in obese people leading to the development of insulin resistance (88, 89). 
This is particularly important in IBC patients where obesity were associated with shorter 
survival (90). CD40-CD40L interaction is the major activator/maturation signaling that 
occur in the lymph node between iDCs and CD4+ T cells to develop adaptive immune 
responses (antigen-specific). This is the central pathway of iDC activation for the 
induction of the antigen-specific cell-mediated anti-tumor responses.    
MiR-146a regulates iDC activation/maturation by regulating TLR4 and CD40 
signaling. Particularly miR-146a can inhibit TLR4 signaling by targeting IRAK1 and 
TRAF6 (91). IRAK1 and TRAF6 are two adaptor proteins activated during TLR4 
signaling. TRAF6 is also a component of the signaling cascade in DC40 pathways (92) 
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The downregulation of IRAK1 and TRAF6 impairs DC maturation induced by TLR4 
and CD40-mediated signaling and important functions, like cytokine production and T 
cell activation (91, 92). MiR-19a can regulate PI3K/Akt-mediate signaling upon the 
binding of LPS and CD40L to TLR4 and CD40 respectively, by the downregulation of 
the phosphatase and tensin homologue (PTEN) a potent inhibitor of PI3K/Akt signaling 
(93, 94). PI3K/Akt signaling plays an important role in promoting survival, migration 
and maturation of DCs (95, 96). Furthermore, miR-19a downregulates the expression of 
SOCS-1 an important negative regulator of IL-6, IL-8 and TLR4 signaling (93, 97, 98). 
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RESEARCH OBJECTIVE  
OVERALL GOAL 
The overall goal of this research project is understand the role of DCs in the tumor 
microenvironment of IBC. Particularly, we wanted to assess how the cross-talk between 
IBC tumor cells and DCs can induce a pro-inflammatory microenvironment responsible 
of the development of tumor cell with aggressive behavior that determine the worse 
clinical outcome of IBC patients. 
CRITICAL OBSERVATION AND CRITICAL QUESTION 
A comprehensive analysis of three large gene expression profile datasets (World 
IBC Consortium) could not establish a unique and definitive molecular signature able to 
distinguish IBC from non-IBC and explain the higher aggressiveness and poor prognosis 
of IBC. Therefore, we asked if the immune cells present in the IBC tumor 
microenvironment can play a role in determining such differences. 
CENTRAL HYPOTHESIS 
 As circulating miRNAs can mediate intercellular communication regulating the gene 
expression of recipient cells 
 As DCs are the master regulator of immune responses in the tumor 
microenvironment and can secrete pro-inflammatory cytokines able to induce the 
development of tumor cells with aggressive characteristics (EMT/CSC-like 
phenotype), we hypothesized that:  
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in the IBC tumor microenvironment miRNAs released by IBC cells 
can be taken up by tumor-associated iDCs and can induce higher levels of 
activation/maturation of iDCs upon stimulation with LPS compared with 
non-IBC cells leading to increased synthesis of pro-inflammatory 
cytokines. 
SPECIFIC AIMS 
Three specific aims are proposed: 
1. show that miRNAs released by breast cancer cells can be taken up by iDCs 
2. show that the taken up miRNAs can regulate DC status and functions: 
a. upregulation of the expression costimulation/activation (CD80, 
CD86, CD40) and maturation (CD83, HLA-DR) surface markers 
b. increase in migration ability 
c. increased synthesis of pro-inflammatory cytokines (IL-6, TNF-). 
3. show that pro-inflammatory secreted by DCs induce tumor cell aggressive 
phenotype: 
a. cancer stem cell-like (CSCs) phenotype 
b. epithelial-to-mesenchymal transition phenotype 
 
Particularly, in an in vitro model of tumor microenvironment, we wanted to assess if 
miR-19a and miR-146a are differentially expressed and released by breast cancer tumor 
cells (IBC vs non-IBC), and if they play a different roles in the regulation of DC 
activation/maturation and functions (cytokine synthesis and migratory ability).  
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Chapter 1: 
Effect of the co-culture with SUM-149 and SUM-159 breast cancer cell 
lines on activation and maturation of DCs upon LPS stimulation 
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SUM-149 and SUM-159 have different effects on DC functions: modulation of the 
expression levels of costimulatory/activation and maturation markers upon DC 
maturation with LPS. 
To test this hypothesis an in vitro model of tumor microenvironment was set up. In 
order to evaluate the effect of soluble factors on DC function, transwell plate with a 
membrane of 1.0 m pore size was used. The size of the pores were big enough to allow 
soluble factors to flow between the two chambers (upper and lower chamber), but small 
enough to prevents tumor cells to migrate across the membrane and to establish a cell-to-
cell contact with DCs. Breast cancer cell lines were plated in the upper chamber and the 
immature dendritic cells (iDCs) in the lower chamber.  
The expression levels of the costimulatory/activation markers (CD80, CD86, CD40) 
and maturation markers (CD83, HLA-DR) are upregulated upon stimulation with LPS 
during the maturation process from immature (iDCs) to mature DCs (mDCs). The 
evaluation of the expression levels of these surface markers is generally used to evaluate 
the degree of activation and maturation of mDCs. 
After 24 h of co-culture with either SUM-149 or SUM-159, iDCs were activated with 
LPS 100 ng/ml for 18 h to induce maturation. When iDCs were previously co-cultured 
with SUM-149 (iDCSUM-149), there was a significant increased upregulation, after 
maturation with LPS, in the expression levels of all the costimulatory/activation and 
maturation markers of mDC SUM-149 compared with those of control mDCs cultured in 
RPMI 10% only (Fig.1).  
  19
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fo
ld
-c
ha
ng
e
mD
C 
cn
tr
SU
M-
14
9
mD
C
SU
M-
15
9
mD
C
0.0
0.5
1.0
1.5
* *
CD80
Fo
ld
-c
ha
ng
e
mD
C 
cn
tr
SU
M-
14
9
mD
C
SU
M-
15
9
mD
C
0.0
0.5
1.0
1.5
* *
CD83
Fo
ld
-c
ha
ng
e
mD
C 
cn
tr
SU
M-
14
9
mD
C
SU
M-
15
9
mD
C
0.0
0.5
1.0
1.5 *
CD40
Fo
ld
-c
ha
ng
e
mD
C 
cn
tr
SU
M-
14
9
mD
C
SU
M-
15
9
mD
C
0.0
0.5
1.0
1.5
* **
*
HLA-DR
Fo
ld
-c
ha
ng
e
mD
C 
cn
tr
SU
M-
14
9
DC
SU
M-
15
9
DC
0.0
0.5
1.0
1.5
2.0
2.5
** ***
*
CD86
  20
Fig. 1. Effect of co-culture with SUM-149 and SUM-159 cells on the expression 
levels of costimulatory/activation and maturation markers of DCs upon stimulation 
with LPS 
Analysis of the upregulation (fold-changes) of the costimulatory/activation (CD80, 
CD86, CD40) and maturation (CD83 and HLA-DR) marker expression levels of mDCs 
(mature DCs) previously co-cultured with SUM-149 (mDCSUM-149) and SUM-159 
(mDCSUM-159) compared with control mDCs (cultured in RPIM 10% FBS) upon LPS 
maturation. The results represent the mean ± standard deviation of 4 independent 
experiments (*p<0.05; **p<0.01; ***p<0.001). 
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On the contrary, when iDCs were previously co-cultured with SUM-159 (iDC SUM-159), 
mDCSUM-159 showed a reduced upregulation, after maturation with LPS, in the 
expression levels of both CD86 and HLA-DR compared with control mDCs cultured in 
RPMI 10% only (Fig.1); while there was not any significant effect on the other surface 
markers (CD80, CD83, CD40). Furthermore, there were also significant differences in 
the upregulation of CD80, CD86, CD83, and HLA-DR of mDCSUM-149 compared with 
mDCSUM-159. This may imply that soluble factors released by SUM-149, during the co-
culture, affected the ability of iDCs to be activated by LPS, inducing a higher degree of 
activation and maturation. This effect has a relevant consequence on the ability of mDC 
to activate T cells, in particularly because the upregulation of CD80, CD86 and HLA-
DR is essential for effective activation of CD4+ and CD8+ T lymphocytes by mature DCs 
(mDCs) during immune responses. Indeed, the lack of CD80, CD86 and HLA-DR 
upregulation can hamper the full activation of CD4+ and CD8+ T lymphocytes and 
induce a suppressed status called anergy. This is one of the major ways by which the 
immune responses are negatively regulated by tumor cells in order to escape by the 
attack of the anti-tumor responses.  
Other breast cancer cell lines were tested for also. No significant differences were 
measured in the degree of upregulation of surface costimulatory/activation markers 
compared with control mDCs, when iDCs were previously co-cultured with the ER/PR+ 
MCF-7 cell line (iDCMCF-7) and the TN MDA-231 cell line (iDCMDA-231), except for the 
CD86 of mDCMCF-7 (Fig.2).  
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Fig. 2. Effect of co-culture with MCF-7 and MDA-231 cells on the expression levels 
of costimulatory/activation and maturation markers of DCs upon stimulation with 
LPS 
Analysis of the upregulation (fold-changes) of the costimulatory/activation (CD80, 
CD86, CD40) and maturation (CD83 and HLA-DR) marker expression levels of mDCs 
(mature DCs) previously co-cultured with MCF-7 (mDCMC-7) and MDA-231 (mDCMDA-
231) compared with control mDCs (cultured in RPIM 10% FBS) upon LPS maturation. 
The results represent the mean ± standard deviation of 3 independent experiments 
(*p<0.05; **p<0.01; ***p<0.001). 
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As SUM-149 is a TN IBC cell line, while SUM-159 is a TN non-IBC cell line we 
evaluated if the effect on DC activation and maturation was associated to the IBC type. 
Therefore, additional IBC cell lines were tested: KPL-4 (HER2+ IBC), SUM-190 
(HER2+ IBC) and IBC-3 (HER2+ IBC). There were not significant differences in the 
degree of upregulation of CD80, CD83 and HLA-DR after LPS maturation, when iDCs 
were previously co-cultured with KPL-4 (iDCKPL-4), SUM-190 (iDCSUM-190) and IBC-3 
(iDCIBC-3) (Fig.3). However, mDCKPL-4, mDCSUM-190, and mDCIBC-3 showed a reduced 
degree in the upregulation of CD86 compared with control mDCs and mDCIBC-3 showed 
a reduced degree in the upregulation of CD40 compared with control mDCs. As KPL-4, 
SUM-190, and IBC-3 are HER2+ IBC cell lines and cannot affect the degree of iDC 
activation and maturation by LPS stimulation, it can be hypothesized that the ability to 
induce an increased activation and maturation of iDCs by LPS might be related to the 
triple negative receptor phenotype of SUM-149. Indeed, it seems that the HER2+ IBC 
phenotype did not have the same effect on iDCs; rather HER2+ IBC phenotype had a 
slightly immunosuppressive effect (Fig.3). It could also be hypothesized that the 
different effect might be related to specific characteristics of SUM-149, like cytokine 
and miRNA expression pattern.  
As the SUM-159 SUM149 cell lines had the most marked differences in affecting the 
degree of activation and maturation of iDCs and they might represent two good cellular 
models to understand the differences between IBC and non-IBC tumor 
microenvironment. Therefore, they were considered for further analyses. However, as 
SUM-149 and SUM-159 are triple negative cell lines, it should be pointed out that they 
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are not representative of all IBC and non-IBC respectively, rather they can be considered 
a model for the study of a subset of tumor microenvironment. 
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Fig. 3. Effect of co-culture with KPL-4, SUM-190 and IBC-3 cells on the expression 
levels of costimulatory/activation and maturation markers of DCs upon stimulation 
with LPS 
Analysis of the upregulation (fold-changes) of the costimulatory/activation (CD80, 
CD86, CD40) and maturation (CD83 and HLA-DR) marker expression levels of mDCs 
(mature DCs) previously co-cultured with KPL-4 (mDCKPL-4), SUM-190 (mDCSUM-190), 
and IBC-3 (mDCIBC-3) compared with control mDCs (cultured in RPIM 10% FBS) upon 
LPS maturation. The results represent the mean ± standard deviation of 4 independent 
experiments (*p<0.05; **p<0.01; ***p<0.001). 
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Chapter 2: 
Effect of the co-culture with SUM-149 and SUM-159 breast cancer cell 
lines on cytokine secretion by DCs 
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SUM-149 and SUM-159 have different effects on on DC functions: cytokine 
secretion by mDCSUM-149 and mDCSUM-159 
Besides the regulation of the expression levels of the surface 
costimulatory/activation and maturation markers of mDCSUM-149 and mDCSUM-159, the 
effect of breast cancer cell-iDC co-culture was also evaluated on another important 
function of mDCs: the production of cytokines. After 24 h of co-culture with SUM-149 
and SUM-159, iDCs were stimulated with LPS 100 ng/ml to induce the synthesis and 
secretion of cytokines. Accordingly with the higher degree of maturation, mDCSUM-149 
produced higher levels of cytokines. Particularly, mDCSUM-149 had a more marked pro-
inflammatory profile of cytokine production than mDCSUM-159. Indeed, mDCSUM-149 
secreted higher levels of IL-1, TNF-, IL-6 and IL-12p40 than mDCSUM-159. 
Furthermore, mDCSUM-149 secreted slightly higher levels of cytokine involved in 
angiogenesis (VEGF and IL-8) than mDCSUM-159 (Fig.4). 
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Fig. 4. Effect of co-culture with SUM-149 and SUM-159 cells on cytokine secretion 
by mDCSUM-149 and mDCSUM-159 
Analysis of cytokine levels in the supernatant of mDCs (mature DCs) previously co-
cultured with SUM-149 (mDCSUM-149) and SUM-159 (mDCSUM-159) compared with 
control mDCs (cultured in RPIM 10% FBS). The results represent the mean ± standard 
deviation of 3 independent experiments except for IL-6 where the data shown are from 
tow experiments (*p<0.05; **p<0.01; ***p<0.001). 
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Chapter 3: 
Effect of the co-culture with SUM-149 and SUM-159 breast cancer cell 
lines on the expression levels of costimulatory/activation and 
maturation markers of iDCs 
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SUM-149 and SUM-159 have different effects on DC functions: modulation of the 
expression levels of costimulatory/activation and maturation status of iDCs 
In order to assess if just the co-culture with SUM-149 and SUM-19 could induce 
changes in the degree of costimulatory/activation and maturation status of iDCs, we 
evaluated the expression pattern of the costimulatory/activation and maturation surface 
markers after 24 of co-culture of iDCs without the stimulation with LPS. We found that 
just the co-culture with SUM-149 determined a general increase of the expression levels 
of the surface markers in iDCSUM-149 compared with control iDCs. Particularly, iDCSUM-
149 had higher expression levels of CD80, CD86, CD83 and HLA-DR compared with 
control iDCs and iDCSUM-159, while iDCSUM-159 had higher expression levels of CD80 and 
CD40 and lower expression levels of HLA-DR compared with control iDCs (Fig.5). 
This may mean that even without maturation with LPS, SUM-149 cells were able to 
induce a higher degree of activation of iDCs compared with iDCSUM-159 and the control 
iDCs.  
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Fig. 5. Effect of co-culture with SUM-149 and SUM-159 cells on the expression 
levels of costimulatory/activation and maturation markers of iDCs 
Analysis of the upregulation (fold-changes) of the costimulatory/activation (CD80, 
CD86, CD40) and maturation (CD83 and HLA-DR) marker expression levels of iDCs 
co-cultured with SUM-149 (mDCSUM-149) and SUM-159 (mDCSUM-159) compared with 
control iDCs (cultured in RPIM 10% FBS) without LPS maturation. The results 
represent the mean ± standard deviation of 2 independent experiments (*p<0.05; 
**p<0.01; ***p<0.001). 
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Chapter 4:  
Effect of the co-culture with SUM-149 and SUM-159 breast cancer cell 
lines on migratory ability of DCs 
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SUM-149 and SUM-159 have different effect on DC functions: migratory ability 
An important function of DCs in controlling the immune responses is their ability to 
migrate in the tissue. To evaluate their migratory ability, a transwell plate with a pore 
size of 8.0 m was used. This pore size allows evaluating active migration by DCs. iDCs 
were plated in the upper chamber of the transwell and conditioned media from MCF-7 
(CM MCF-7), SUM-149 (CM SUM-149) and SUM-159 (CM SUM-159) were used as 
migration stimuli and loaded in the lower chamber. The CM SUM-149 induced higher 
rate of migration of iDCs, compared with CM MCF-7, CM SUM-159 medium and 
RMPI 10% alone (Fig.6a). Then, the effect of co-culturing iDCs with MCF-7, SUM-149 
and SUM-159 on migratory ability was evaluated. After 48 h of co-culture, iDCMCF-7 and 
iDCSUM-159 showed lower migratory ability compared with control, while iDCSUM-149 
showed a higher migratory ability compared with control iDCs. Furthermore, iDCSUM-149 
showed a higher migratory ability compared with iDCSUM-159 (Fig.6b). Therefore, SUM-
149 cells secreted chemotactic factors able to stimulate higher migration of iDCs 
compared with MCF-7 and SUM-159 and the co-culture of iDCs with breast cancer cell 
line further increased these differences. These results confirmed that SUM-149 cells can 
increase the degree of activation of iDCs and their functions. It can be hypothesized that, 
in the tumor microenvironment, TN IBC cells can attract iDCs to the tumor site and 
induce an upregulation of their functions. 
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Fig. 6. Effect of co-culture with SUM-149 and SUM-159 cells on migratory ability 
of DCs 
Migration ability of iDCs (a) and, iDCMCF-7, iDCSUM-159 and iDCSUM-149 (b) using 
conditioned media from MCF-7 (CM MCF-7), SUM-149 (CM SUM-159) and SUM-149 
(CM SUM-149). In (a) it is shown the most representative experiment; in (b) the results 
represent the mean ± standard deviation of one experiment performed in triplicate 
(*p<0.05; **p<0.01; ***p<0.001). 
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Chapter 5: 
Transfer of miRNAs from SUM-149 and SUM-159 breast cancer cells 
to iDCs 
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MiRNAs can be transferred from SUM-149 and SUM-159 to iDCs 
As miRNAs can be secreted into extracellular space as circulating miRNAs in a 
very stable form, are functional and can mediate intercellular communication, we 
hypothesized that circulating miRNAs can also traffic between breast cancer cells and 
iDCs and in this way they can regulate the genes expression and activation of iDCs. 
MiRNAs can be released into extracellular space either inside microvesicles 
(exosomes and apoptotic bodies) or in a cell-membrane-free form as Ago2-miRNA 
complex, thus we use two approach to track exosomes and miRNA: stain breast cancer 
cell with the green fluorescent dye PKH67 and transfect breast cancer cell with Dy547-
labeled miRNA. PKH67 is a green fluorescent dye used for cell membrane labeling 
characterized by long aliphatic carbon tail that allow the dye to be trapped inside the cell 
membrane lipid bilayer preventing the leaking or cell-to-cell transfer, while Dy547-
labeled miRNA is a non-targeting red fluorescent miRNA used as mimic negative 
control for miRNA transfection. The same transwell setting of co-culture was utilized 
(1.0 m pore size) to assess the transfer of exosomes and miRNAs from SUM-149 and 
SUM-159 to iDCs. First, we labeled SUM-149 and SUM-159 with green fluorescent dye 
PKH67 and plated in the upper chamber of transwell. As PKH67 can be incorporated in 
all cell membranes, it can also stain exosomes.  
After 24 h of co-culture in transwell, the uptake of PKH67-labeled exosomes by 
iDCs could be detected by fluorescence microscopy, confocal microscopy and flow 
cytometry, as shown in fig.7-8. To confirm that miRNAs are transferred to iDCs, SUM-
149 and SUM-159 were transfected with Dy547-labeled miRNA. After 24 h of culture, 
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cell viability was checked (>90%) before plating the transfected SUM-149 and SUM-
159 into the upper chamber of the transwell. Also in this case, fluorescent staining could 
be detected in iDCs after 48 h of co-culture (fig.9). 
To further confirm the transfer to iDCs, exosomes were purified from the 
supernatants of both PKH67-labeled SUM-149 and SUM-159. To prevent the 
contamination of cellular debris, the supernatants were centrifuged at high speed (3000 
X g for 15 minutes) before the precipitation at 4oC according to the manufacturer’s 
instruction. A further step to remove possible contaminating debris was added by 
filtering the centrifuged supernatant through a 0.2 m filter. The purified PKH67-labeled 
exosomes were added to iDCs for 24h of culture. The confocal microscopy analysis 
confirmed the uptake of exosome by iDCs (fig.10). 
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Fig. 7. Exosome transfer from PKH67-labeled SUM-149 and SUM-159 cells 
analyzed by fluorescence microcopy 
Fluorescence microcopy and FACS analysis of: a) control iDCs; b) iDCs co-cultured 24 
h with SUM-149; c) iDCs co-cultured 24 h with SUM-159. SUM-149 and SUM-159 
were previously stained with the green fluorescent dye PKH67 and then plated in the 
upper chamber of 1.0 m pore size transwell.  
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Fig. 8. Exosome transfer from PKH67-labeled SUM-149 and SUM-159 cells 
analyzed by confocal fluorescence microcopy 
Confocal fluorescence microcopy analysis of: a) control iDCs; b) iDCs co-cultured for 
24 h with SUM-149; and c) iDCs co-cultured 24 h with SUM-159. SUM-149 and SUM-
159 were previously stained with the green fluorescent dye PKH67 and then plated in 
the upper chamber of 1.0 m pore size transwell. On the right side: DAPI and FITC 
fluorescence overlapping with bright field images of iDCs. 
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Fig. 9. Exosome transfer from SUM-149 and SUM-159 cells transfected with 
Dy547-labeled miRNAs analyzed by confocal fluorescence microcopy  
Confocal fluorescence microcopy analysis of: a) control iDCs; b) iDCs co-cultured for 
48 h with SUM-149; c) iDCs co-cultured for 48 h with SUM-159. SUM-149 and SUM-
159 were previously transfected with red fluorescent Dy547-labeled miRNA and than 
plated in the upper chamber of 1.0 m pore size transwell. On the right side: DAPI and 
TRITC fluorescence overlapping with bright field images of iDCs. 
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Fig. 10. Transfer of exosomes isolate from PKH67-labeled SUM-149 and SUM-159 
cells analyzed by confocal fluorescence microcopy 
Confocal fluorescence microcopy analysis of; a) control iDCs; b) iDCs co-cultured 24h 
with exosome isolated from PKH67-labeled SUM-149; c) iDCs co-cultured 24h with 
exosome isolated from PKH67-labeled SUM-159. 
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Chapter 6: 
Expression levels of miR-19a and miR-146a in breast cancer cell lines 
and their cell culture supernatants 
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MiR-19a and miR-146a are differentially expressed by SUM-149 and SUM-159 and 
they can be detected in the cell culture media and exosomes isolated from the 
supernatants. 
The expression of miR-19a and miR-146a was evaluated in SUM-149, SUM-159 
cells line and their supernatants. For further comparison, the expression levels of these 
two miRNAs were also evaluated in additional cell lines: HMLE; MCF-7; MDA-231; 
KPL-4; SUM-190; and IBC-3.  
SUM-149 cells expressed higher levels of miR-19a compared with SUM-159 (~2.7-
fold higher). HMLE, MCF-7, MDA-231, KPL-4, SUM-190 and IBC-3 cells expressed 
lower levels of miR-19a compared with SUM-149 (Fig. 11a). On the contrary, SUM-159 
expressed very high levels of miR-146a compared with SUM-149 (~240-fold higher). 
Only MDA-231 expressed moderately high levels of miR-146a compared with SUM-
159, while miR-146a levels were much lower in HMLE, MCF-7, MDA-231, KPL-4, 
SUM-190 and IBC-3 compared with SUM-159 (Fig. 11b). To verify that miR-19a and 
miR-146a can be released by the breast cancer cells, we evaluated the levels of miR-19a 
and miR-146a in the supernatants of SUM-149 and SUM-159. Only the supernatants of 
cell line with viability > 90% were used. The supernatant of SUM-149 had higher level 
of miR-19a compared with the supernatant of SUM-159 (~1.9-fold higher). MCF-7, 
MDA-232, KPL-4, SUM-190 and IBC-3, released very low levels of miR-19a compared 
with SUM-149 (Fig. 12a). The supernatant of SUM-159 had very high levels of miR-
146a compared with the supernatant of SUM-149 (~53-fold higher). Only the 
supernatant of MDA-231 had fairly high amount of miR-146a, while the supernatant of 
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MCF-7, MDA-232, KPL-4, SUM-190 and IBC-3 had very low levels of miR-146a 
compared with SUM-159 (Fig. 12b).  
Finally, we evaluated if the exosomes isolated from the supernatants of SUM-149 
and SUM-159 contained miR-19a and miR-146a. Exosomes from both cell lines 
contained miR-19a and miR-146a. Exosomes from SUM-149 had higher levels of miR-
19a than miR-146a (~22-fold higher), while exosomes from SUM-159 had comparable 
levels of miR-146a and miR-19a (Fig. 13a-b). 
We can conclude that miR-19a and miR-146a are selectively expressed and released 
in the supernatant by SUM-149 and SUM-159. 
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Fig. 11. Expression levels of miR-19a and miR-146a in breast cancer cell lines 
Expression levels of miR-19a (a) and miR-146a (b) in HMLE, SUM-149, SUM-159 
MCF-7, MDA-231, KPL-4 SUM-190 and IBC-3 cell lines. The expression levels of 
miR-19a and miR-146a are from the most representative experiment. 
  56
a 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Circulating miR-19a
m
iR
-1
9a
/U
6 
sn
R
N
A
SU
M-
14
9
SU
M-
15
9
MC
F-7
MD
A-
23
1
KP
L-4
SU
M-
19
0
IB
C-
3
0
1
2
3
4
Circulating miR-146a
m
iR
-1
46
a/
U
6 
sn
R
N
A
SU
M-
14
9
SU
M-
15
9
MC
F-7
MD
A-
23
1
KP
L-4
SU
M-
19
0
IB
C-
3
0.00
0.05
0.10
0.15
2
4
6
  57
Fig. 12. Expression levels of miR-19a and miR-146a in the supernatants of breast 
cancer cell lines 
Expression levels of miR-19a (a) and miR-146a (b) in the supernatants of: HMLE, 
SUM-149, SUM-159 MCF-7, MDA-231, KPL-4 SUM-190 and IBC-3 cell lines. The 
expression levels of miR-19a and miR-146a are from the most representative 
experiment. 
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Fig. 13. Exosomes released by SUM-149 and SUM-159 cells contain miR-19a and 
miR-146a 
Detection of miR-19a and miR-146a in the exosomes isolated from SUM-149 (a) and 
SUM-159 (b) supernatants. The expression levels of miR-19a and miR-146a are from 
one experiment. 
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Chapter 7: 
Transfer of miR-19a and miR-146a from breast cancer cell lines to 
iDCs 
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MiR-19a and miR-146a can be transferred from breast cancer cells to recipient 
iDCs  
In order to assess if miR-19a and miR-146a can be transferred to iDCs, SUM-149 
and SUM-159 were transfected respectively with 100 nM mimic miR-19a (SUM-149miR-
19a) and miR-146a (SUM-159miR-146a) and co-cultured with iDCs in transwell 1.0 m 
pores size. After 24 h of co-culture, there was a significant increase in the levels of miR-
19a and miR-146a in iDCs co-cultured with SUM-149miR-19a (Fig. 14a) and SUM-159miR-
146a (Fig. 14b) respectively. We also assessed if the co-culture of non-transfected SUM-
149 and SUM-159 could influence the levels of miR-19a and miR-146a. Indeed, the co-
culture with SUM-149 and SUM-159 induced an increase of miR-19a (Fig. 15a) and 
miR-146a (Fig. 15b) in iDCs, respectively. 
We can conclude that miR-19a and miR-146a can be transferred from SUM-149 and 
SUM-159 to iDCs, respectively. 
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Fig. 14. Transfer of miR-19a and miR-146a from transfected SUM-149 and SUM-
159 cells to iDCs 
Expression levels of miR-19a and miR-146a in iDCs co-cultured with: a) SUM-149 
transfected with miRIDIAN mimic miR-19a (SUM-149miR-19a); b) SUM-159 transfected 
with miRIDIAN mimic miR-146a (SUM-159miR-146a), than plated in the upper chamber 
of 1.0 m pore size transwell. The results represent the mean ± standard deviation of one 
experiment performed in triplicate (*p<0.05; **p<0.01; ***p<0.001). 
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Fig. 15. Transfer of miR-19a and miR-146a from SUM-149 and SUM-159 cells to 
iDCs 
Expression levels of miR-19a and miR-146a in iDCs co-cultured with SUM-149 (a) and 
SUM-159 (b) for 24 h in 1.0 m pore size transwell. The expression levels of miR-19a 
and miR-146a are from the most representative experiment. 
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Chapter 8: 
Effect of miR-19a and miR-146a on the mRNA levels of their target 
genes PTEN, SOCS-1, IRAK1, TAF6 and cytokine in DCs 
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The miR-19a and miR-146a affect the levels of cytokine mRNA synthesis in mDCs 
To assess the effect of miR-19a and miR-146a on cytokine production, iDCs were 
transfected with mimic miR-19a 50 nM and miR-146a 100 nM. The transfection of iDCs 
with miR-19a (iDCmiR-19a) induced a decrease in the expression levels of its target genes 
PTEN and SOCS-1 compared with iDCs transfected with mimic control (iDCmock) (Fig. 
16a). After stimulation with LPS 100 ng/ml for 3 h, iDCmiR-19a produced higher mRNA 
levels of IL-6 and TNF- compared with iDCmock (Fig. 16b). On the contrary, the 
transfection of iDCs with miR-146a (iDCmiR-146a) induced a decrease in the expression 
levels of its target genes IRAK1 and TRAF6 compared with iDCs transfected with 
mimic control (iDCmock) (Fig. 17a). After stimulation with LPS 100 ng/ml for 3 h, 
iDCmiR-146a produced lower mRNA levels of IL-6 and TNF- compared with iDCmock 
(Fig. 17b). We can conclude that increased levels of miR-19a in iDCs were able to 
enhance the ability to synthesize the pro-inflammatory cytokines IL-6 and TNF- upon 
LPS activation. Therefore, miR-19a can induce a more pro-inflammatory phenotype in 
iDCmiR-19a. On the other hand, increased levels of miR-146a in iDCs reduced the ability 
to synthesize IL-6 and TNF- upon LPS activation. Therefore, miR-146a can induce an 
anti-inflammatory phenotype in iDCmiR-146a. 
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Fig. 16. Effect of transfection with miR-19a mimic on PTEN and SOCS-1 mRNA 
levels and on IL-6 and TNF-a mRNA levels in DCs 
Expression levels of PTEN and SOCS-1 mRNA in iDCs transfected with miR-19a in (a) 
and the levels of IL-6 and TNF- mRNA after LPS stimulation in (b). The results are 
from the most representative experiment. 
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Fig. 17. Effect of transfection with miR-146a mimic on IRAK1 and TRAF6 mRNA 
levels and on IL-6 and TNF-a mRNA levels in DCs  
Expression levels of IRAK1 and TRAF6 mRNA in iDCs transfected with miR-146a in 
(a) and the levels of IL-6 and TNF- mRNA after LPS stimulation in (b). The results 
represent the mean ± standard deviation of one experiment performed in triplicate 
(*p<0.05; **p<0.01; ***p<0.001). 
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Chapter 9: 
Effect of IL-6 on miR-19a and miR-146a levels in SUN-149 and SUM-
159 cells 
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Effect of IL-6 on miR-19a and miR-146a expression levels in SUM-149 and SUM-
159 
As SUM-149 and SUM-159 cells could influence the synthesis of pro-inflammatory 
cytokines in mDCSUM-149 and mDCSUM-159, we wanted to asses if those cytokines could 
affect in turn the levels of miR-19a and miR-146a in SUM-149 and SUM-159 cells. IL-6 
could increase the levels of miR-19a in SUM-149 cells, with the strongest induction at 
10 ng/ml, but it had no effect in SUM-159 cells (Fig. 18a). On the other hand, IL-6 
induced a modest increase of miR-146a levels in SUM-149 cells, that remained ~37-fold 
lower than those in SUM-159, while in SUM-159 IL-6 (5 ng/ml) could upregulate the 
expression levels of miR-146a to a values ~208-fold higher than those in SUM-149 and 
this effect decreased with the increase of IL-6 concentration (Fig. 18b).  
We can conclude that IL-6 had different effect on the expression of miR-19a and 
miR-146a in SUM-149 and SUM-159. It can be hypothesized that in the SUM-149 
model of IBC tumor microenvironment, the IL-6/miR-19a axis represents a self-
sustaining loop able to maintain a pro-inflammatory status of DCs. While in the SUM-
159 model of non-IBC tumor microenvironment, IL-6/miR-146a may represent a self-
limiting loop that maintains an immune suppressed status of DCs. 
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Fig. 18. Effect of IL-6 on miR-19a and miR-146a expression levels in SUM-149 and 
SUM-159 cells 
Dose-dependent effect on the expression levels of miR-19a (a) and miR-146a (b) in 
SUM-149 and SUM-159 after 24 h of IL-6 stimulation. The results are from the most 
representative experiment. 
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Chapter 10: 
miR-19a levels in SUM-149 with EMT and CSC-like phenotype 
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Increased levels of miR-19a in SUM-149 cells are associated with EMT and CSC-
like phenotype  
SUM149 is a mixed cell line exhibiting two distinct CD44/CD24 populations, 
CD44+CD24- and CD44+CD24+, that are characterized by basal-like (spindle-like 
appearance) or luminal-like (epithelial-like appearance) features respectively [79]. As 
IL-6 is produced by SUM-149 (99), induced EMT in breast cancer (53, 54), regulated 
the survival and growth of breast cancer CSCs (100), and induced miR-19a synthesis in 
SUM-149, we assessed if increased levels of miR-19a can be associated with an 
enrichment of CSCs (CD44+CD24- ALDH+) with EMT characteristics (expression of 
EMT-regulating gene: Twist1, Snail1, Snail2, TG2, FOXC2, ZEB1),.  
When they were allowed to grow to 80-90% of confluence in a long-term cell 
culture (5-7 days) without changing the culture medium, SUM-149 cells acquired 
spindle-like appearance (SUM-149EMT cells) resembling cancer cells with EMT 
phenotype, compared with SUM-149 (SUM-149Regular cells) that are grown in canonical 
conditions (40-50% confluence for 3 days)(Fig. 19). Furthermore, SUM-149EMT cell 
culture was enriched in the CD44+ population (Fig. 20a) and in cells with increased 
ALDH activity (ALDH1+)(Fig. 20b). As IL-6 regulates the growth and survival of 
CD44+CD24- breast cancer stem cells and IL-6 is produced by SUM-149, we assumed 
that the long-term cell culture could have increased levels of IL-6. Thus, we measured 
IL-6 levels in the SUM-149EMT and SUM-149Regular cell culture supernatants. We found 
that SUM-149EMT cell culture had higher levels of IL-6 compared with those of SUM-
149Regular and HMLE used as control (Fig. 21).  
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Fig. 19. Induction of EMT phenotype in SUM-149 cells by long-term cell culture  
SUM-149 cells cultured under different cell culture conditions: canonical (3 days and 
40-50% confluence) and long-term culture without changing culture medium (5-7 days 
and 80-90% confluence). Four representative pictures are shown. 
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Fig. 20. Enrichment of SUM-149 cell subset with CSC-like phenotype by long-term 
cell culture 
Enrichment of the population with cancer stem cell (CSC)-like phenotype (CD44+CD24- 
and ALDH1+) in SUM-149 cell culture under different conditions: canonical (3 days) 
and long-term (6-7 days, without changing of culture medium). In (a) it is shown that the 
long-term cell culture condition induced an enrichment of the CD44+CD24- population 
and in (b) it is shown that the long-term cell culture induce the enrichment of tumor cells 
with increased ALDH activity. The doplot in (a) and (b) are from the most representative 
experiment. The Aldefluor chart results represent the mean ± standard deviation of 3 
independent experiments (*p<0.05; **p<0.01; ***p<0.001). 
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Fig. 21. Increased levels of IL-6 in the supernatant of SUM-149EMT cells from long-
term cell culture  
The supernatant of SUM-149EMT cells from ling-term cell culture Levels had increased 
levels of IL-6 compared with the supernatant of HMLE (human mammary epithelial 
cells) and SUM-149Regular cells. 
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It was previously reported that IL-6 can induce EMT in breast cancer cells (53, 54) 
and that EMT breast cancer cells have CSCs phenotype (101). As in our study, we 
showed that IL-6 induced miR-19a synthesis, we evaluated if SUM-149EMT cells, beside 
an enrichment of tumor cells with CSC phenotype, had also EMT characteristics. We 
found that SUM-149EMT cells expressed higher levels of the master regulator of EMT 
(Twist1, Snail1, Snail2, TG2, FOXC2), the EMT markers (N-cadherin, vimentin), 
EGFR, E-cadherin and most importantly higher levels of miR-19a compared with SUM-
149Regular cells (Fig. 22). It is noteworthy that EGFR-mediated signaling was shown to be 
involved in regulating EMT in IBC (102) and E-cadherin plays important role in tumor 
emboli formation (103) and is associated with poor outcome in IBC (103, 104). Finally, 
IL-6 could also increase the expression levels of miR-155 in SUM-149 (Fig. 23), and 
miR-155 was reported to regulates TGF--induced EMT (105) and induce 
chemoresistance in breast cancer (106).  
We can conclude that increased levels of miR-19a might be associated with the 
enrichment in the population of SUM-149 cells with EMT and CSC phenotype and that 
IL-6 might play an important role in regulating this phenomenon. Therefore, in the 
tumor microenvironment the increased levels of IL-6 might drive the development of 
tumor cells responsible of the more aggressive behavior of IBC. Further studies are 
required to assess the role of IL-6 in the induction of EMT and CSC phenotype in SUM-
149 cells. 
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Fig. 22. Increased expression of EMT-regulating genes and miR-19a in SUM-149 
cells from long-term cell culture  
SUM-149EMT cells from ling-term cell culture expressed higher levels of the EMT-
regulating genes (Twist1, Snail1, Snail2, TG2, FOXC2), the EMT markers (N-cadherin, 
vimentin), EGFR and E-cadherin in SUM-149EMT compared with SUM-149Regular cells. 
Results of gene expression levels are from the most representative experiment. The 
expression levels of miR-19a in SUM-149EMT and SUM-149Regular cells represent the 
mean ± standard deviation of 3 independent experiments (*p<0.05; **p<0.01; 
***p<0.001). 
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Fig. 23. Effect of IL-6 on miR-155 expression levels in SUM-149 and SUM-159 cells 
Dose-dependent effect on the expression levels of miR-155 in SUM-149 and SUM-159 
after 24 h of IL-6 stimulation. The results are from the most representative experiment. 
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Chapter 11: 
Serum levels of miR-19a and clinical outcome in breast cancer patients 
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MiR-19a serum levels are predictive of favorable clinical outcome of metastatic 
IBC patients  
MiRNAs released by tumor cells in the tumor microenvironment can gain access to 
the bloodstream through the newly formed blood vessels around the tumor. 
Consequently, tumor cell-derived miRNAs can be detected in the serum as circulating 
miRNAs and may reflect the dysregulated pattern of the parental tumor. Therefore, 
circulating miRNAs can be used as serum biomarkers for IBC. 
As miR-19a is differentially expressed and secreted by SUM-149 and SUM-159 and 
had a significant different impact on DC functions, we wanted to assess if differences in 
levels of miR-19a were also present between the serum of IBC and non-IBC patients and 
if they correlated with clinical outcome. We evaluated the serum levels of miR-19a in 35 
non-metastatic (16 locally advanced breast cancer [LABC], and 16 IBC) and 64 
metastatic (27 metastatic non-IBC [MNIBC], and 37 metastatic IBC, [MIBC]) breast 
cancer patients. While in M0 cohort we did not find significant differences between IBC 
and LABC patients, in M1 cohort MIBC had higher median levels of miR-19a than 
MNIBC (p=0.010) (Fig. 24a). Then, we evaluated if there was a correlation between the 
serum levels of miR-19a and the clinical outcome. In M0 cohort there was no 
correlation; however, in the M1 cohort MIBC patients with high serum levels of miR-
19a had longer progression-free survival (PFS: 7.9 vs. 3.0 months; p=0.031) and overall 
survival (OS: 24.6 vs. 11.7; p=0.018) than patients with low levels of miR-19a (Fig. 
24b). Similar pattern of survival was found also in MNIBC but the differences in the 
survival curve were not statistically significant. These results apparently seem to 
  91
contradict our in vitro model, in which SUM-149 secreted higher level of miR-19a and 
induced higher levels of pro-inflammatory cytokines responsible of the development of 
tumor cells with aggressive features. However, increased miR-19-mediated activation of 
DCs leads to increased levels of costimulatory molecules that are necessary for T cell 
activation. Consequently, a more effective T cell mediated immune response can be 
achieved.  Depending on which T cell mediated immune response is elicited (Th1, Th2, 
Th-17), different results can occur with different effects on clinical outcome: 1) Th1 
lymphocytes can induce an anti-tumor responses mediated by CD8+ CTL and NK cells; 
2) Th2 lymphocytes inhibit the anti-tumor responses induced by Th1 lymphocytes; and 
3) Th-17 lymphocytes mediate a tumor promoting pro-inflammatory responses. Several 
factors can affect miR-19a serum levels in different ways and they will be examined in 
the discussion. 
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Fig.24. Levels of miR-19a in the serum of breast cancer patients and clinical 
outcome 
In a) levels of miR-19a in the serum of MNIBC and MIBC compare with HDs; b) 
Kaplan-Meier plots of MIBC patients according to the serum levels of miR-19a. Patients 
with high levels of serum miR-19a had longer PFS (7.9 vs. 3.0 months; p=0.031); and 
OS (24.6 vs. 11.7; p=0.018).  
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Table 1. Clinical characteristics of breast cancer patients at the beginning of the study 
and their association with serum miR-19a levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
miR-19a, n (%) 
Characteristic n Low High P 
Age at sample collection 
(years) 
54    
< 45 21 7 (15) 14 (26) .221 
≥ 45 78 39 (84) 39 (74)  
Race     
Asian 5 4 (9) 1 (2) .348 
African-American 5 3 (7) 2 (4)  
Hispanic 7 4 (9) 3 (6)  
Non-Hispanic white 82 35 (76) 47 (89)  
IBC     
Yes 56 21 (46) 35 (66) .045 
No 43 25 (54) 18 (34)  
Stage     
M0 35 17 (37) 18 (34) .834 
M1 64 29 (63) 35 (66)  
Grade     
1 3 2 (5) 1 (2) .292 
2 26 15 (34) 11 (21)  
3 67 27 (61) 40 (77)  
Hormone receptor     
Positive 63 34 (74) 29 (55) .060 
Negative 36 12 (26) 24 (45)  
HER2     
Positive 51 24 (52) 27 (51) 1.000 
Negative 48 22 (48) 26 (49)  
Triple-negative status     
Yes 18 4 (9) 14 (26) .035 
No 81 42 (91) 39 (74)  
  95
DISCUSSION 
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IBC is a very aggressive form of locally advanced breast cancer (LABC) 
characterized by high ability to invade, grow and spread in the dermal lymphatics of the 
skin of the breast. Its higher aggressiveness is responsible of worse prognosis compared 
to non-IBC. So far, little is known about the molecular mechanism that can explain such 
differences in clinical outcome. Indeed, recent studies performing gene expression 
profiling by the World IBC Consortium could not identify a definitive molecular 
signature able to explain the difference in the behavior of tumor cells between IBC and 
non-IBC. Moreover, the National Cancer Institute’s Surveillance, Epidemiology and End 
Results (SEER) reported that contrary to the decreasing trend of non-IBC, the incidence 
of IBC is continuously increasing (19). Therefore, the discovery of new biomarkers and 
molecular targets for IBC are needed. 
In the tumor microenvironment, the complex network of interactions between 
cancer cells and tumor associated cells play a central role in driving tumor development 
and progression. Particularly, paracrine crosstalk between cancer and bystander cells in 
the tumor microenvironment could regulate tumor dissemination at early stage, even 
before the primary tumor is clinically detectable. Indeed, tumor associated immune cells 
can regulate the dissemination of tumor cells in two opposite ways. They can limit the 
spread of tumor cells by activating an anti-tumor immune response (43, 44), or they can 
promote tumor progression by their chronic activation and secretion of pro-inflammatory 
cytokines (IL-6, IL-8, TNF-) responsible of the development and expansion of tumor 
cells with CSC-like and EMT characteristics. 
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As DCs play a central role in the regulation of the immune response, we hypothesized 
that the cell-free miRNAs released from IBC cells can be taken up and affect the 
functions of TADC in term of increased migratory ability toward IBC cells and 
production of pro-inflammatory cytokine IL-6, IL-8, TNF-. 
In an in vitro model of tumor microenvironment, we found that the TN IBC cells 
SUM-149 could induce an increased migration, activation and production of IL-6, IL-8, 
and TNF- compared with the TN non-IBC SUM-159 cells. This was mediated by the 
differential expression and release into the culture medium of miR-19a and miR-146a by 
SUM-149 and SUM-159 respectively. The uptake of miR-19a had a pro-inflammatory 
effect, while that of miR-146a had an anti-inflammatory effect. MiR-19a can target 
PTEN in B cells and induce its downregulation PTEN (85). It was shown that in DCs the 
downregulation of PTEN by siRNA regulated the PI3K/Akt-mediated signaling and 
promoted maturation, activation, migration and survival of DCs (95, 96). Furthermore, 
PI3K/Akt signaling regulated the generation and differentiation of immature monocytes-
derived dendritic cells (MoDCs) by GM-CSF and IL-4 signaling (107) and the increased 
survival by the anti-apoptotic signal of adipocyte-derived hormone leptin (108). This 
may be relevant in IBC, as obesity was found to be associated with an increased risk of 
IBC patients (109, 110) and breast cancer patients with high body mass index had high 
levels of leptin (110).  
In our study, we showed that miR-19a could reduce the expression of PTEN and 
increase the activation of DC in term of pro-inflammatory cytokine production. 
Furthermore, PI3K signaling can mediate a negative feedback regulation of production 
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of IL-12 by DC (111). IL-12 plays a central role in the induction of an anti-tumor 
immune response (Th1-mediated immune response). Therefore, in the IBC tumor 
microenvironment, the uptake of miR-19a released from tumor cells may have a dual 
effect on tumor-associated DCs. Indeed, the downregulation of PTEN in tumor-
associated DCs can induce an increased activation and production of pro-inflammatory 
cytokine, but on the other hand it can limit an effective anti-tumor response by reducing 
the levels of IL-12.  
MiR-146a can target the two adapter molecules IRAK1 and TRAF6 that regulate 
IL-1, TLR and CD40 signaling (91, 112). IL-1-, TLR- and CD40-mediated signaling 
pathways are important in the process of maturation and activation of DCs. Therefore, 
the downregulation of IRAK1 and TRAF6 hamper the full activation of DC and 
accordingly the pro-inflammatory responses (113-115). Therefore, in the non-IBC tumor 
microenvironment, the uptake of miR-146a released from tumor cells may induce a 
downregulation of DC functions resulting in reduced ability to produce pro-
inflammatory cytokines and stimulate an effective anti-tumor response.  
Which role do the pro-inflammatory cytokines (IL-6, IL-8, TNF-) have in the 
tumor microenvironment? In the IL-6 signaling cascade, the binding of IL-6 to its 
receptor IL-6R activates STAT3 (116) and STAT3 is a transcription factor that regulate 
miR-19a synthesis (117). We showed that IL-6 stimulation was able to induce an 
upregulation of miR-19a synthesis in SUM-149. Therefore, in the IBC tumor 
microenvironment, the increased activation of DC by the uptake of miR-19a can induce 
an upregulation of IL-6 production by DCs that in turn can further stimulate SUM-149 to 
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synthesize IL-6 in a self-sustaining loop. Moreover, miR-19a can induce downregulation 
of SOCS-1 (98), a negative regulator of IL-6R, determining and increase in IL-6R-
mediated signaling in cancer cells. Recently, it was reported that IL-6 is able to induce 
EMT in breast cancer (53, 54) cells and sustain growth and proliferation of 
CD44+CD24+ stem cell-like breast cancer cells (100). We showed that IL-6 could also 
increase the synthesis of miR-155 in SUM-149. It was reported that the pro-
inflammatory cytokines IFN- and IL-6 induced upregulation of miR-155 expression 
(118) and miR-155 regulates TGF--induced EMT (105) and induces chemoresistance 
(106). Moreover, miR-155 overexpression promotes breast cancer cell proliferation, 
migration, invasion both in vitro and in vivo and tumor development in nude mice (61). 
As we showed that increased levels of miR-19a were associated to the expansion of 
CD44+CD24+ population with EMT-like characteristics both miR19a and miR-155 
might represent a marker for EMT in this population of cells. Indeed, we showed that 
transcription factors regulating EMT were upregulated in CD44+CD24+ cells of SUM-
149 and also E-cadherin, an important adhesion molecule responsible of the tumor 
emboli formation (103). Moreover, IL-6 can induce the expression of the chemokine 
receptor CXCR4 in breast cancer and the CXCR4/CXCL12 axis may be involved in 
driving the metastatic process to the bone (119-121). It was reported that, as breast 
cancer start to disseminate to the bone there is an increase in DC population within the 
bone that induce tumor progression and bone loss (122). So, DCs might have a role in 
inside the bone that sustains the survival and proliferation of TN IBC cells with 
CSC/EMT-like characteristics.  
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Therefore, the crasstalk between IBC cells and DCs mediated by IL-6 and miR-19a 
in the TN IBC tumor microenvironment might be responsible of the induction of a 
population of cells with CSC/EMT-like characteristics that can disseminate even at early 
stage of tumor development and be responsible of the poor prognosis. 
Also IL-8 is involved in the regulation of CSCs. Indeed, it can regulate the self-
renewal of breast CSCS and PTEN is negative regulator of IL-8R signaling (51). 
Therefore, the IL-6-mediated increase of the levels of miR-19a in IBC cells can sustain 
the proliferation and survival of CSCs by downregulating PTEN and increasing IL-8 
signaling. It was reported that IL-8 is also involved in regulation of angiogenesis, 
invasion in breast cancer (123) and in the retention of DCs at tumor site, that prevents 
the migration to lymph nodes and the induction of an anti-tumor immune response (124). 
We showed that SUM-149 and SUM-159 can produce IL-8 and that the culture medium 
of SUM-149 could induce a higher degree of migration in iDCs. It can be hypothesized 
that IBC cells can attract iDCs present in tissue surrounding the tumor more efficiently 
and enhance their activation and functions through the release of miR-19a inside the 
exosomes. It can also be hypothesized the exosomes may have an effect also at level of 
lymph nodes. Indeed, exosomes can flow inside the lymphatic vessels and reach either 
locoregional or distant lymph nodes, where they can induce activation of dendritic cells. 
Particularly, we showed that mDCSUM-149 could produce higher levels of IL-8, compared 
mDCSUM-159. It was reported that SUM-149 cells express the receptors for IL-8 (CXCR1 
and CXCR2) and that IL-8 signaling may function as chemotatic factor, induce 
fibronectin expression, induce morphology changes towards a migratory spindle-like 
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phenotype through PI3K/Akt signaling pathway (125). Therefore, mDCSUM-149 present in 
the lymph nodes might play a role in the dermal lymphatic invasion.   
Besides regulating IL-8 signaling, increased levels of miR-19a might also play a 
direct role in the regulation of neoangiogenesis in IBC. Indeed, it was reported that 
overexpression of miR-19a can induce higher levels of neovascularization in Kras-
transformed mouse colonocytes, by targeting the anti-angiogenic regulator 
thrombospondin-1 (Tsp1) (84). Therefore, increased levels of miR-19a in IBC cells 
might have a role in regulating neoangiogenesis in the TN IBC tumor microenvironment 
by targeting Tsp1 and inducing higher level of IL-8 in TADC.  
Also TNF- was reported to induce the EMT and enhance invasiveness and 
migratory properties of breast cancer cells (126-130). Indeed, chronic stimulation with 
TNF- can induce EMT and CSC properties in normal breast epithelial and cancer cells 
by the upregulation of Twist1 and Snail through NF-kB activation (130, 131). Moreover, 
TNF- can increase the levels of ceramide in MCF-7 (132, 133) and ceramide was 
found to trigger the secretion of exosomes (64). Therefore, the increased levels of TNF-
 in the TN IBC microenvironment might contribute to the development of breast cancer 
cells with CSC/EMT-like characteristics and increased the secretion of exosome from 
IBC cells.  
MiR-19a released in the tumor microenvironment may reach the peripheral blood 
circulation through the newly formed blood vessels around the tumor. Therefore, high 
levels of miR-19a can potentially be measured in the serum of IBC patients with tumor 
expressing high levels of miR-19a and correlate with poor outcome. However, besides 
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tumor cells, other cell type can contribute to the levels of miRNAs in the serum. Indeed, 
it should be observed that most of the circulating miRNAs originate from blood cells, 
particularly immune cells (77), and may be expressed also in tumor. Thus, it is not easy 
to distinguish the individual contribution to the serum levels of miRNAs. It can be 
assumed that the levels of circulating miRNA may represent the general 
clinicopathological condition of the cancer patients and originate from both blood and 
tumor cells.  
Several factors may affect serum levels of miR-19a. We showed that miR-19a 
released from SUM-149 cells can induce an increased activation and maturation of DCs 
and to secrete higher levels of pro-inflammatory cytokines that may be responsible of 
poor IBC outcome. On the other hand increased activation and maturation of DCs is 
accompanied by upregulation of costimulatory molecules that consequently leads to an 
increased ability to activate different subset of T lymphocytes: Th1, Th2, and Th17. In 
turn, T lymphocytes can migrate to tumor site where they carry out their effector 
functions as tumor-associated (TAL) or tumor-infiltrating lymphocytes (TIL). Th1 
lymphocytes can induce an anti-tumor responses mediated by CD8+ CTL and NK cells 
and the presence of tumor-associated CD8+ T cells is a favorable prognostic factor in 
breast cancer (134, 135). Recently, it was reported that antigen-specific effector CD8+ 
CTL and Th1 lymphocytes upregulate miR-19a upon activation (136, 137) and 
lymphocytes can release miRNAs through exosome secretion (73). Therefore, increased 
serum levels of miR-19a can result from an effective Th1-induced anti-tumor immune 
response that may be responsible for the good prognosis. Moreover, an effective anti-
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tumor response mediated by CD8+ CTL and NK cells can determine an extensive IBC 
tumor cell death, causing an increased release of cellular miRNA and therefore 
contributing to high levels of miR-19a in patients with good prognosis. Indeed, we 
showed that high levels of miR-19a in the serum of MIBC patients correlated with a 
better clinical outcome. It can be hypothesized that IBC patients with poor outcome are 
unable to develop an effective anti-tumor immune response, evidenced by low levels of 
miR-19a in the serum. Moreover, the miR-19a detected in the serum might originate in 
part by IBC cells with aggressive features, such CSC/EMT-like phenotype. 
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CONCLUSION 
We concluded that the TN IBC cell line SUM-149 can represent a valuable model to 
study the effect of tumor microenvironment crosstalk between IBC and tumor associated 
DCs. In particular, SUM-149 can affect the function of DCs through the release of miR-
19a that subsequently can be taken up by DCs, leading to a higher activation status and 
responsiveness to stimulatory signals by downregulating PTEN and SOCS-1 (PI3K/Akt, 
CD40, IL-6, IL-8 and TNF- signaling). In turn, the increased activation of DCs 
determined a higher secretion of pro-inflammatory cytokines (IL-6 and TNF-) that 
induced the development of tumor cells with aggressive characteristics (EMT/CSC-like 
phenotype) responsible of tumor progression and poor prognosis in IBC patients. On the 
other hand, serum miR-19a may represent a valuable prognostic serum biomarker for 
MIBC patient with good clinical outcome.  
 
 
 
 
 
 
 
  105
CAVEAT AND WEAKNESS 
 
Transfer of miRNAs from breast cancer cells to iDCs 
We hypothesized that miRNAs are released by breast cancer cells and are taken 
up by iDCs. Several studies showed that miRNAs can be physiologically released 
by normal and tumor cells through three mechanisms such apoptosis, necrosis, and 
active secretion (68, 69, 133) either encapsulated inside exosomes or in a complex 
with Ago2. Our in vitro model is a controlled system in which the viability of breast 
cancer cell lines was always > 90% across different experiments. The caveat is that 
we can exclude that the mechanism of miRNA release in our model is necrosis or 
apoptosis. This can represent a weakness, as our in vitro model may represent only 
partially the overall mechanism of miRNA transfer in the tumor microenvironment. 
Indeed, apoptosis and necrosis can have a relevant impact on extracellular miRNA 
levels in vivo, as multiple factor can influence the tumor cell viability (hypoxia, 
nutrient availability, chemo- and radiotherapy, cellular and soluble apoptotic signals 
delivered by immune cells).  
To further prove our hypothesis of miRNA transfer, several approaches may be 
used. Particularly, miRNA transfer can be inhibited by targeting either the secretion 
or the uptake of miRNAs. The process of secretion through exocytosis can be 
inhibited by culturing breast cancer cells at 4oC, or using secretion inhibitor 
chemicals, like brefeldin A (BFA) or cytochalasin. Furthermore, recently it was 
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reported that miRNA can be secreted through ceramide-dependent pathway (64), 
thus this strategy to inhibit the secretion of miRNA can be pursued. On the other 
hand, the uptake of miRNAs can be targeted by EDTA (reduction of free Ca2+), 
fixation with paraformaldehyde. 
 
Effect of miRNA uptake on DC functions 
The second point of our hypothesis was that the transfer of miRNAs can affect DC 
function (activation, maturation, migration and cytokine synthesis). The weakness of our 
experimental design is that we did not completely prove that miR-19a and miR-146a, 
released from SUM-149 and SUM-159 respectively, were the major player in regulating 
DC functions. Indeed, we only used mimic miR-19a and miR-146a to increase their 
levels on DCs, but other miRNAs may be involved. Furthermore, in addition to 
miRNAs, exosomes contain mRNA, DNA and proteins with regulatory functions (70, 
72, 138). Therefore, it is necessary to assess if the knocking down miR-19a and miR-
146a can inhibit respectively the pro- and anti-inflammatory functions of DCs.  
Another weakness is that we evaluated the effect of the miR-19a and miR-146a 
overexpression only on cytokine synthesis. To fully demonstrate the effect of breast 
cancer miRNA transfer on DC functions, it is necessary to assess the effect of both 
mimic and inhibitor miR-19a and miR-146a on the expression of 
costimulatory/activation, maturation surface markers and migration of DCs.  
Finally, additional breast cancer cell lines could be used to prove the role of miR-
19a and miR-146a in the regulation DC functions. As MCF-7 and MDA-231did not 
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affect DC functions when co-cultured in transwell and expressed low levels of miR-19a 
and miR-146a compared with SUM-149 and SUM-159, they can be transfected with 
miR-19a and miR-146a mimic and co-cultured with iDCs.  
 
SUM-149 and SUM-159 are not representative of all IBC and non-IBC 
In our study, we proposed SUM-149 as a model for IBC. It should be pointed out 
that SUM-149 is not representative of all IBC, as this is TN IBC. Thus, SUM-149 may 
be a valuable model for patients with TN IBC with subtype. Indeed, when we used the 
HER2+ IBC cell lines KPL-4, SUM-190, and IBC-3, we did not observe significant 
changes in DC functions (costimulatory/activation and maturation surface markers). 
Furthermore, due to tumor heterogeneity, this model could be valid only for a subset of 
patients within the same subtype. In support of this hypothesis, the two non-IBC TN 
breast cancer cell lines SUM-159 and MDA-231 had significant different effects on DC 
functions. Further studies are required to establish the molecular signature of SUM-149 
and SUM-159 that are responsible of the different effects on DC functions. This would 
help the identification of subsets of patients within the TN subtype (IBC and non-IBC) 
with considerably different clinical outcome. 
 
IL-6-mediated induction of EMT 
We showed that long-term cell culture induced the enrichment of SUM-149 cells 
with EMT and CSC phenotype. This process was associated to an increase in the levels 
of IL-6 in the cell culture supernatant. A caveat is that we did not demonstrate the direct 
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effect of IL-6 in the induction of EMT and CSC expansion. Indeed, it may be an effect 
rather than the cause. Therefore, it is required to prove the direct effect of IL-6 in this 
setting, by the use of either recombinant IL-6 and anti-IL-6 blocking antibody in the 
SUM-149 cell culture.  
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MATERIAL AND METHODS 
Material and Methods 
Cell lines 
The human breast cancer cell lines MCF-7 (ER/PR+), MDA-231 (ER/PR-, HER2-
triple negative: TN), KPL-4 (HER2+, inflammatory breast cancer) were obtained from 
the American Type Culture Collection (Manassas, VA) and maintained in culture with 
DMEM/F-12 medium supplemented with 10% FBS (Tissue Culture Biologicals, Seal 
Beach, CA) and 1% of Antibiotic-Antimycotic 100X (Gibco, Carlsbad, CA). The two 
TN cell lines SUM149 (IBC) and SUM-159 (non-IBC), SUM-190 (HER2+, 
inflammatory breast cancer), kindly provided by Dr. N. Ueno (The Morgan Welch 
Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD 
Anderson Cancer Center, TX) and IBC-3 (HER2+, inflammatory breast cancer), kindly 
provided by Dr. W. Woodward (Radiation Oncology, The University of Texas MD 
Anderson Cancer Center) were maintained in culture with Ham’s/F-12 medium 
supplemented with % FBS (Tissue Culture Biologicals, Seal Beach, CA), 5 g/mL 
insulin, 1 g/mL hydrocortisone and 1% of Antibiotic-Antimycotic 100X (Gibco, 
Carlsbad, CA). The immortalized human mammary epithelial cells (HMLE) were kindly 
provided by Dr. S. Mani (Molecular Pathology, The University of Texas MD Anderson 
Cancer Center) and were maintained in DME: F12 media (1:1) supplemented with 
insulin, EGF, hydrocortisone and 5% calf serum.  
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Generation of DCs from monocytes 
 Immature dendritic cells (iDCs) were generated from monocytes isolated from 
peripheral blood mononuclear cells (PBMCs) of healthy donors. Particularly, PBMCs 
isolated from total blood by Ficoll-Hypaque density centrifugation were plated in T-75 
flasks (Costar Corning, Corning, NY) at a density of 4 × 106 cells/mL of RMPI 10% 
FBS and allowed monocytes to adhere to the plastic of the flasks. After ~4 h at 37oC, 
non-adherent cells were removed with two washes and monocytes were cultured 5 days 
in RMPI 10% FBS supplemented with rhIL-4 1000 U/ml (R&D Systems, Minneapolis, 
MN) and GM-CSF 1000 U/ml (Leukine, Berlex, Richmond, CA). At day 2, 2 mL of 
spent culture medium were replenished with 2 mL of fresh RMPI 10% FBS with rhIL-4 
1000 U/ml and GM-CSF 1000 U/ml. At day 5 iDCs were harvested and used for co-
culture experiments. To induce maturation, iDCs were stimulated with LPS 100 ng/ml 
(Lipopolysaccharide from E. coli J5, Sigma, St. Louis, CA). 
  
FACS analysis 
 The differentiation and the maturation of iDCs were evaluated assessing the 
expression of CD80, CD86, CD83, CD40, HLA-DR and CD11c (BD Biosciences, San 
Jose, CA) using phycoerythrin-coupled (PE) antibodies anti-CD80, CD86, CD83, CD40, 
HLA-DR and allophycocyanin-coupled (APC) antibody anti-CD11c. SUM-149 cells 
were evaluated for the presence of breast cancer stem cells (BCSCs) by expression of the 
CD44 and CD24 surface markers and the ALDH enzymatic activity using fluorescein 
isothiocyanate-coupled (FITC) antibody anti-CD44, PE antibody anti-CD24 (BD 
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Biosciences) and ALDEFLUOR™ Kit (Stem Cell Technologies). FACS analysis was 
carried out using BD™ LSR II flow cytometer (BD Biosciences) and analyzed using 
FlowJo software Version 8.8.6 (TreeStar).  
 
Transwell co-culture 
 To prevent cell-to-cell contact and evaluate the effect of soluble factors released by 
breast cancer cells on DC functions, cultures in transwell were performed. Transwell 
with 1.0 m pore size membrane (Millipore, Temecula, CA) were used and 0.3 X 106 
breast cancer cells/well were plated in the upper chamber and 0.1 x 106 iDCs/well  were 
plated in the lower chamber of 24-well plate (Corning Costar, NY). RPMI 10% FBS was 
used as culture medium in all co-culture experiments. The cells were cultured at 37oC for 
different time (24 or 48 h) according to the experimental setting.  
 
Exosome and miRNA transfer 
 To assess the transfer of miRNAs from breast cancer cells to iDCs, SUM-149 and 
SUM-159 cells were labeled with PKH67 green fluorescent membrane linker-dye 
(Sigma) following the manufacturer’s instructions and transfected with Dy547-labeled 
meridian mimic negative control (Dharmacon, Lafayette, CO). After extensive washing 
steps, PKH67-labeled SUM-149 and SUM-159 cells (0.3 X 106 cells/well) were plated in 
the upper chamber of Transwell (1.0 m pore size membrane) and 0.1 x 106 iDCs/well 
were plated in the lower chamber of 24-well plate. After 24 h of culture, iDCs were 
harvested and analyzed for fluorescent exosome uptake. Briefly, iDCs cells were fixed 
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with 1 mL of PBS 4% paraformaldehyde for 1 h at 4oC, then the cell suspension was 
washed in PBS and centrifuged onto microscope glass slides using cytospin centrifuge 
(Cytopro, Wescor Inc., Logan, UT) at 400 rpm for 5 minutes. Finally, SlowFade Gold 
Antifade reagent with DAPI (Invitrogen) was added to the slides to stain nuclei and 
protect fluorescent dye from photo-bleaching. Pictures were captured by either Nikon 
Eclipse 80i fluorescence microscopy or Olympus FV1000 laser-scanning confocal 
microscopy and the images were analyzed with NIS-Elemnts BR 3.1 and Olympus 
Fluoview (Ver.3.0 Viewer) respectively. The transfer of exosomes to iDCs was also 
evaluated by FACS analysis. To further confirm the transfer from breast cancer cells to 
iDCs, exosomes were isolated from the supernatants of PKH67-labeled SUM-149 and 
SUM-159 cells using exosome precipitation solution (Exo-Quick, System Biosciences) 
according to the manufacturer’s instructions, added to iDCs and cultured for 24 h. Then, 
iDCs were harvest an analyzed for fluorescent exosome uptake with laser-scanning 
confocal microscopy (Olympus FV1000).  
 
RNA extraction and qRT-PCR 
 Total RNA was isolated from DCs, breast cancer cell lines, exosomes, cell culture 
supernatant, and breast cancer patient serum using the Total RNA Purification Kit 
(Norgen Biotek Corporation, Thorold, ON, Canada) following the manufacturer’s 
instructions. For the miRNAs extracted from supernatants, it was used the culture 
medium of cell line with 70-80% confluence and viability >90%. Supernatants were 
centrifuged at 3000 rpm for 15 minutes and than filtered through 0.2 mm filter to remove 
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cellular debris. The concentration of total RNA was measured by NanoDrop 2000 
Spectrophotometer (Thermo Scientific, Wilmington, DE) and then RNA was 
immediately stored at -80oC. Total RNA isolated was reversed transcribed to cDNA 
using either TaqMan MicroRNA Reverse Transcription Kit or High Capacity cDNA 
Reverse Transcription Kit for miRNA and gene expression analysis respectively 
(Applied Biosystems, Foster City, CA). Briefly, for miRNA expression analysis 10 ng of 
total RNA were reverse transcribed in a total volume reaction of 15 L, following the 
manufacturer’s instructions. The reaction was performed using the Veriti Thermal 
Cycler (Applied Biosystems) at 16 oC for 30 minutes, 42oC for 30 minutes and 85oC for 
5 minutes. For gene expression analysis, 300 ng of total RNA were reverse transcribed 
in a total volume reaction of 50 L and the reaction was performed at 25oC for 10 
minutes, 37oC for 120 minutes and 85oC for 5 minutes. The expression levels of 
miRNAs and genes were measured by qRT-PCR using the TaqMan MicroRNA or Gene 
Expression Assays (Applied Biosystems) according to the manufacturer’s instructions. 
The reaction was performed using the 7900HT Fast Real-Time PCR Systems (Applied 
Biosystems, Foster City, CA) at 95oC for 10 minutes and 40 cycles at 95oC for 15 
seconds and 60oC for 60 seconds. The relative expression of miRNAs and genes was 
calculated using the equation 2-Ct, where Ct = mean CtmiRNA/gene – mean CtU6 
snRNA/GAPDH, Ct = threshold cycle. 
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Breast cancer cell line and iDC transfection 
 To confirm the transfer of miRNAs from breast cancer cell lines to iDC, SUM-149 
and SUM-159 cells were transfect with 100 nM miRIDIAN mimics has-miR-19a and 
hsa-miR-146a respectively (Dharmacon) at the concentration of 0.1 X 106 cells/well in 
24-well plats using DharmaFECT transfection reagent (Dharmacon). After 24 h at 37oC 
transfected cells were extensively washed and maintained in culture for additional 24h in 
their culture medium. Then, 0.1 X 106 cells/well of transfected SUM-149 and SUM-159 
cells were plated in the upper chamber of Transwell (1.0 m pore size membrane) and 
0.1 X 106 iDCs/well were plated in the lower chamber of 24-well plate and cultured for 
24 h at 37oC. The levels of miR-19a and miR-146a were evaluated in iDCs by qRT-
PCR.  
 To evaluate the effect of miR-19a and miR-146a on the expression levels of their 
target genes and on cytokines production, iDCs were transfected with 50 nM miRIDIAN 
mimics has-miR-19a and 100 nM miRIDIAN mimics hsa-miR-146a for 24-48 h and 
then PTEN, SOCS-1, IRAK1 and TRAF6 mRNA levels were evaluated by qRT-PCR. 
IL-6 and TNF- mRNA levels were measured after 3 h stimulation with LPS 100ng/ml. 
 
Luminex Bead Array Assay for cytokine detection 
 To evaluate the effect on the levels of secreted cytokines, iDCs were co-cultured 
with SUM-149 and SUM-159 cells in Transwell (1.0 m pore size membrane). Briefly, 
0.3 X 106 cells/well of either SUM-149 or SUM-159 cells were plated in the upper 
chamber and 0.1 X 106 iDCs/well were plated in the lower chamber of 24-well plate for 
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24 h. To induce maturation and synthesis of cytokines, iDCs were stimulated with LPS 
100 ng/ml for 18 h. The supernatants were collected, centrifuged and cytokine levels 
were evaluated using Milliplex MAP Human Cytokine/Chemokine Panel following the 
manufacturer's instructions (EMD Millipore, Billerica, MA) and analyzed by a Luminex 
100 Analyzer running BioPlex 4.2 Software (Bio-Rad). 
 
Cell migration assay 
 The migratory ability of DCs was evaluated in Transwell Chamber with 8.0 m 
pore size membrane. Briefly, 5 X 105 cells/well were plated in the upper chamber in 
RPMI serum-free and culture for 16 h. The conditioned media from MCF-7, SUM-149 
and SUM-159 cells were used as migration stimuli. Conditioned media were prepared by 
culturing MCF-7, SUM-149 and SUM-159 cells in RMPI 10 FBS for 24-48 h until 70-
80% cell confluence. Then the supernatants were centrifuged 2000 g for 10 minutes and 
filtered to remove cellular debris. The iDCs that migrated into the lower chamber were 
counted under microscopy using Neubauer chambers and the chemotactic index was 
calculated as number of iDCs that migrated to MCF-7, SUM-149 and SUM-159 
conditioned media divided by number of iDCs that migrated to RPMI 10%. We also 
evaluated the migratory ability of iDCs that were previously co-culture with MCF-7, 
SUM-149 and SUM-159 cells in Transwell (1.0 m pore size membrane) using the same 
experimental setting used for iDCs. 
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Detection of miR-19a in the serum of breast cancer patients 
Ninety nine breast cancer patients were enrolled in 2 laboratory-based protocols 
approved by the institutional review board at The University of Texas MD Anderson 
Cancer Center (Houston, Texas) consisting in: 35 non-metastatic (16 locally advanced 
breast cancer [LABC], and 16 IBC) and 64 metastatic (27 metastatic non-IBC [MNIBC], 
and 37 metastatic IBC, [MIBC]) breast cancer patients. Serum was collected, after 
written informed consent was obtained, from all patients at the beginning of the study 
(before a new line of therapy for patients with M1 disease and before first-line therapy 
for patients with M0 disease). Serum were also collected from age-matched healthy 
donors (HDs) and used as a control. Patients’ clinical and histopathological information 
is summarized in Table 1. 
 The serum was isolated from 10 mL of peripheral blood of breast cancer patients 
and HDs in BD Vacutainer serum tubes (Becton Dickinson Vacutainer, Franklin Lakes, 
NJ). Thirty minutes at ambient temperature were used to allow the blood to clot, and 
then the serum was separated by centrifugation within 3-4 h after phlebotomy and stored 
at -80°C in 1 mL aliquots. Total RNA was isolated using the Total RNA Purification Kit 
(Norgen Biotek Corporation, Thorold, ON, Canada) following the manufacturer’s 
instructions, starting with 100 L of serum. 
 
Statistical analysis 
 The differences in the expression levels of CD80, CD86, CD40, CD80, HLA-DR, 
ALDH1, miRNAs, and genes were evaluated using GraphPad Prism 5.04 software 
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(GraphPad Software Inc., San Diego, CA). The two-tailed Student’s paired and unpaired 
t test was used for the statistical analysis. The non-parametric 2-tailed Mann Whitney-U 
test was used to compare serum levels of miR-19a in the different groups of patients. 
The Kaplan-Meier method was used to evaluate the differences of progression-free 
survival (PFS) and overall survival (OS) durations of breast cancer patients that were 
divided in two groups according to levels of miR-19a: patients with high and low levels 
of miR-19a. To define high and low levels of miR-19a, we used a cut-off that 
corresponded to the mean values of each miRNA in the serum of HDs plus 2 standard 
deviations. The survival duration was calculated from the date of sample collection at 
the beginning of the study. A log-rank test was used to analyze the differences between 
groups and analyzed using GraphPad Prism 5.04 software. The p-values <0.05 were 
considered statistically significant (p<0.05 is indicated with: *; p<0.01 is indicated with: 
**; p<0.001 is indicated with: ***). 
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